RVNC
Revance Therapeutics Inc
Price:  
3.65 
USD
Volume:  
4,122,600.00
United States | Pharmaceuticals
Valuation
Overview
Financials
Forecast
Compare
Historical Price
SolvencyDividends
Transactions
People

RVNC EV/EBITDA

-697.4%
Upside

As of 2025-07-09, the EV/EBITDA ratio of Revance Therapeutics Inc (RVNC) is -4.67. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. RVNC's latest enterprise value is 764.47 mil USD. RVNC's TTM EBITDA according to its financial statements is -163.87 mil USD. Dividing these 2 quantities gives us the above RVNC EV/EBITDA ratio.

Note: valuation result may not be accurate due to the company's negative EBITDA.

Range Selected
Trailing P/E multiples 7.2x - 10.3x 8.2x
Forward P/E multiples 11.2x - 17.7x 14.9x
Fair Price (21.29) - (19.90) (21.80)
Upside -683.2% - -645.3% -697.4%
3.65 USD
Stock Price
(21.80) USD
Fair Price

RVNC EV/EBITDA - Historical EV/EBITDA Data

Date EV/EBITDA